Stock DNA
Pharmaceuticals & Biotechnology
EUR 2,579 Million (Small Cap)
22.00
NA
1.49%
0.02
7.97%
1.76
Revenue and Profits:
Net Sales:
185 Million
(Quarterly Results - Mar 2016)
Net Profit:
22 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-96.19%
0%
-96.19%
6 Months
-96.19%
0%
-96.19%
1 Year
-96.19%
0%
-96.19%
2 Years
-96.19%
0%
-96.19%
3 Years
-92.63%
0%
-92.63%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Almirall SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-4.15%
EBIT Growth (5y)
21.66%
EBIT to Interest (avg)
-7.82
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.02
Sales to Capital Employed (avg)
0.39
Tax Ratio
25.52%
Dividend Payout Ratio
310.50%
Pledged Shares
0
Institutional Holding
0.99%
ROCE (avg)
4.32%
ROE (avg)
24.28%
Valuation key factors
Factor
Value
P/E Ratio
22
Industry P/E
Price to Book Value
1.76
EV to EBIT
54.10
EV to EBITDA
20.64
EV to Capital Employed
1.75
EV to Sales
3.77
PEG Ratio
NA
Dividend Yield
1.49%
ROCE (Latest)
3.24%
ROE (Latest)
7.97%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'16 - YoY
Mar'16
Mar'15
Change(%)
Net Sales
184.90
180.00
2.72%
Operating Profit (PBDIT) excl Other Income
38.70
35.40
9.32%
Interest
4.70
2.70
74.07%
Exceptional Items
0.00
0.00
Consolidate Net Profit
21.70
42.90
-49.42%
Operating Profit Margin (Excl OI)
88.20%
92.80%
-0.46%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2016 is 2.72% vs -10.71% in Mar 2015
Consolidated Net Profit
YoY Growth in quarter ended Mar 2016 is -49.42% vs 304.72% in Mar 2015
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
985.70
894.50
10.20%
Operating Profit (PBDIT) excl Other Income
184.60
164.20
12.42%
Interest
16.40
15.40
6.49%
Exceptional Items
-10.00
-45.90
78.21%
Consolidate Net Profit
10.10
-38.50
126.23%
Operating Profit Margin (Excl OI)
46.10%
44.60%
0.15%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 10.20% vs 3.63% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 126.23% vs -995.35% in Dec 2023
About Almirall SA 
Almirall SA
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






